Why was the Q4 loss so large?

The headline loss of ₹29.77 crore was dominated by a ₹23.01 crore impairment charge on its subsidiary, Lyka BDR International. The company had already disclosed this write-down in a previous filing.

Was there any new, negative information in these results?

No. The impairment was pre-disclosed, and revenue was described as broadly stable. The results formalize previously known numbers without adding a new negative surprise.

What else happened procedurally?

The board set a record date for share issuance under a previously sanctioned amalgamation scheme and scheduled the annual general meeting. These are standard corporate actions.

Earnings · Pharmaceuticals · Micro cap

Lyka Labs' Q4 loss is ₹29.77 cr. Most of it was already known.

A ₹23 cr subsidiary impairment, disclosed earlier, eats up the bulk of the quarter's net loss. The results confirm old news.

— 1 earlier story on Lyka Labs Ltd. →

LYKALABS By Tipsheet Editorial 25 May 2026 · 3:47 PM IST Verify on BSE · NSE

Mkt cap₹253 cr

ROE7.74%

Debt / eq.0.37

₹29.77 cr Standalone net loss for Q4 FY26.

What's new

Lyka Labs approved Q4 and FY26 audited results; standalone net loss was ₹29.77 cr.
The loss was driven by a ₹23.01 cr impairment in subsidiary Lyka BDR International.
Revenue was broadly stable quarter-on-quarter.

Why this matters

A ₹29.77 crore net loss looks alarming until you see that ₹23.01 crore of it is an impairment charge the company already told the market about. Strip that out, and the underlying operational loss is much smaller. The results confirm the bad news, not break it.

What we're watching

Any future steps to restructure or sell Lyka BDR International post-impairment.
How the amalgamation scheme, now past its record date, reshapes the group structure.
Trend in operational revenue and costs once the one-off write-down is behind the numbers.

The full read

Lyka Labs' Q4 loss is ₹29.77 crore. Mostly noise. ₹23.01 crore of it is a subsidiary impairment at Lyka BDR International, a hit the company had already flagged. Revenue was broadly stable. The filing also processed a record date for the group amalgamation and set the AGM. What remains is the operational story. Strip out the known write-down, and the loss shrinks dramatically. The real question is what happens to Lyka BDR now.

Questions answered

Why was the Q4 loss so large?: The headline loss of ₹29.77 crore was dominated by a ₹23.01 crore impairment charge on its subsidiary, Lyka BDR International. The company had already disclosed this write-down in a previous filing.
Was there any new, negative information in these results?: No. The impairment was pre-disclosed, and revenue was described as broadly stable. The results formalize previously known numbers without adding a new negative surprise.
What else happened procedurally?: The board set a record date for share issuance under a previously sanctioned amalgamation scheme and scheduled the annual general meeting. These are standard corporate actions.

Mentioned: Lyka BDR International · ₹23.01 cr impairment · Q4 FY26

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on LYKALABS →

25 May 2026 · 3:47 PM IST Lyka Labs' Q4 loss is ₹29.77 cr. Most of it was already known.
42d ago Lyka Labs writes off ₹23 cr in subsidiary, posts annual loss